PanGenomic Health (AQSE:NARA) Debt-to-EBITDA : -0.41 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is PanGenomic Health Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PanGenomic Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.37 Mil. PanGenomic Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.00 Mil. PanGenomic Health's annualized EBITDA for the quarter that ended in Sep. 2023 was £-0.92 Mil. PanGenomic Health's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.41.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PanGenomic Health's Debt-to-EBITDA or its related term are showing as below:

AQSE:NARA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.05 Med: -0.01 Max: -0.01
Current: -0.05

During the past 2 years, the highest Debt-to-EBITDA Ratio of PanGenomic Health was -0.01. The lowest was -0.05. And the median was -0.01.

AQSE:NARA's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Healthcare Providers & Services industry
Industry Median: 2.55 vs AQSE:NARA: -0.05

PanGenomic Health Debt-to-EBITDA Historical Data

The historical data trend for PanGenomic Health's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PanGenomic Health Debt-to-EBITDA Chart

PanGenomic Health Annual Data

Trend

Dec21

Dec22

Debt-to-EBITDA

-0.01

PanGenomic Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial					-	-	-0.04	-0.13	-0.41

Competitive Comparison of PanGenomic Health's Debt-to-EBITDA

For the Health Information Services subindustry, PanGenomic Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PanGenomic Health's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PanGenomic Health's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PanGenomic Health's Debt-to-EBITDA falls into.

PanGenomic Health Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PanGenomic Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.062	+	0)	/	-7.241
	=	-0.01

PanGenomic Health's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.374	+	0)	/	-0.92
	=	-0.41

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

PanGenomic Health (AQSE:NARA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PanGenomic Health Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PanGenomic Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PanGenomic Health (AQSE:NARA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » PanGenomic Health Inc (AQSE:NARA) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

LL31:Germany NARA:Canada

Address

3800 Wesbrook Mall, Suite 102, Vancouver, BC, CAN, V6S 2L9

Website

https://www.pangenomic.com

PanGenomic Health Inc is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provides consumers with a knowledge base tailored to an individual's user profile, developed by tracking a user's treatment regimen and their specific genomic, proteomics, and microbiome data. The Company's mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

PanGenomic Health (AQSE:NARA) Headlines

No Headlines